REFERENCES
1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26-38.
2. Street W. Cancer facts & figures 2019. 1930:76.
3. Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterol Hepatol Bed Bench 2011;4:175-85.
4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
5. Angell HK, Lee J, Kim KM, Kim K, Kim ST, et al. PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. Oncoimmunology 2019;8:e1544442.
6. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 2018;24:1449-58.
8. Balfour HH Jr, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunol 2015;4:e33.
9. Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964;283:702-3.
10. Dalldorf G, Linsell CA, Barnhart FE, Martyn R. An epidemiologic approach to the lymphomas of African children and Burkitt’s sacroma of the jaws. Perspect Biol Med 1964;7:435-49.
11. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000;34:27-53.
12. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 1994;91:9131-5.
13. Ribeiro J, Oliveira A, Malta M, Oliveira C, Silva F, et al. Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal. World J Gastroenterol 2017;23:7292-302.
14. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, et al. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 2004;320:330-6.
15. Nogueira C, Mota M, Gradiz R, Cipriano MA, Caramelo F, et al. Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Portugal. Infect Agent Cancer 2017;12:41.
16. Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, et al. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest 1994;71:73-81.
17. Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 2018;66:15-22.
18. Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget 2016;7:32925-32.
19. Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol 2019;234:16824-37.
20. Cao S, Wylie KM, Wyczalkowski MA, Karpova A, Ley J, et al. Dynamic host immune response in virus-associated cancers. Commun Biol 2019;2:109.
21. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013.
22. Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 2019;24:103-9.
23. Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702.
24. Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol 2019;12:1756284819869767.
25. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017;3:1051-8.
26. Cho J, Chang YH, Heo YJ, Kim S, Kim NK, et al. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open 2018;3:e000326.
27. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 2019;25:3753-8.
28. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
29. Borozan I, Zapatka M, Frappier L, Ferretti V. Analysis of Epstein-Barr virus genomes and expression profiles in gastric adenocarcinoma. J Virol 2018;92:e01239-17.
30. Song H, Lim Y, Im H, Bae JM, Kang GH, et al. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus). Sci Rep 2019;9:3465.
31. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 2013;9:e1003341.
32. Camargo MC, Kim KM, Matsuo K, Torres J, Liao LM, et al. Circulating antibodies against Epstein-Barr virus (EBV) and p53 in EBV-positive and -negative gastric cancer. Cancer Epidemiol Biomarkers Prev 2020;29:414-9.
33. Yi K, Ju YS. Patterns and mechanisms of structural variations in human cancer. Exp Mol Med 2018;50:98.
34. Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 2019;33:1687-99.
35. Saito R, Abe H, Kunita A, Yamashita H, Seto Y, et al. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol 2017;30:427-39.
36. Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J 2019;9:73.
37. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, et al. Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature 2016;534:402-6.
38. Xu M, Zhang WL, Zhu Q, Zhang S, Yao YY, et al. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. Theranostics 2019;9:1115-24.
40. Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients. Sci Rep 2017;7:45124.
41. Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, et al. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Hum Pathol 2017;68:103-11.
42. Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, et al. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. Gene 2017;599:28-35.
43. Wu Y, Zhao T, Jia Z, Cao D, Cao X, et al. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. J Gastroenterol Hepatol 2019;34:1201-7.
44. Wang W, Sun J, Li F, Li R, Gu Y, et al. A frequent somatic mutation in CD274 3’-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat 2012;33:480-4.
45. Wang Q, Lin W, Tang X, Li S, Guo L, et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int J Mol Sci 2017;18:2540.
46. Wang F, Li T, Zhang B, Li H, Wu Q, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013;434:688-94.
47. Wang Y, Wang D, Xie G, Yin Y, Zhao E, et al. MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. Oncotarget 2017;8:28125-34.
48. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
49. Treece AL, Duncan DL, Tang W, Elmore S, Morgan DR, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Invest 2016;96:661-71.
50. Alessandrini L, Manchi M, De Re V, Dolcetti R, Canzonieri V. Proposed molecular and miRNA classification of gastric cancer. Int J Mol Sci 2018;19:1683.
51. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015;6:6472-98.
52. Marquitz AR, Mathur A, Chugh PE, Dittmer DP, Raab-Traub N. Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol 2014;88:1389-93.
53. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 2010;70:4719-27.
54. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, et al. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer 2013;119:304-12.
55. Queen KJ, Shi M, Zhang F, Cvek U, Scott RS. Epstein-Barr virus-induced epigenetic alterations following transient infection. Int J Cancer 2013;132:2076-86.
56. Li Y, Nie Y, Tu S, Wang H, Zhou Y, et al. Epigenetically deregulated miR-200c is involved in a negative feedback loop with DNMT3a in gastric cancer cells. Oncol Rep 2016;36:2108-16.
57. Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 2019;33:132-47.
58. Zhou Y, Ding BZ, Lin YP, Wang HB. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene 2018;644:56-65.
59. Kim SM, Hur DY, Hong SW, Kim JH. EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells. Biochem Biophys Res Commun 2017;494:550-5.
60. Otsuka H, Fukao A, Funakami Y, Duncan KE, Fujiwara T. Emerging evidence of translational control by AU-rich element-binding proteins. Front Genet 2019;10:332.
61. Guo J, Qu H, Shan T, Chen Y, Chen Y, et al. Tristetraprolin overexpression in gastric cancer cells suppresses PD-L1 expression and inhibits tumor progression by enhancing antitumor immunity. Mol Cells 2018;41:653-64.
62. Deng K, Wang H, Shan T, Chen Y, Zhou H, et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci Rep 2016;6:24505.
63. Sung WW, Chu YC, Chen PR, Liao MH, Lee JW. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells. Cancer Lett 2016;382:21-31.
64. Wang M, Yu F, Wu W, Wang Y, Ding H, et al. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. Int J Biol Sci 2018;14:565-76.
65. Hooykaas MJ, Kruse E, Wiertz EJ, Lebbink RJ. Comprehensive profiling of functional Epstein-Barr virus miRNA expression in human cell lines. BMC Genomics 2016;17:644.
66. Qiu J, Smith P, Leahy L, Thorley-Lawson DA. The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS Pathog 2015;11:e1004561.
67. Yang YC, Liem A, Lambert PF, Sugden B. Dissecting the regulation of EBV’s BART miRNAs in carcinomas. Virology 2017;505:148-54.
68. Zhang J, Huang T, Zhou Y, Cheng ASL, Yu J, et al. The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Cell Mol Med 2018;22:38-45.
69. Tsai CY, Liu YY, Liu KH, Hsu JT, Chen TC, et al. Comprehensive profiling of virus microRNAs of Epstein-Barr virus-associated gastric carcinoma: highlighting the interactions of ebv-Bart9 and host tumor cells. J Gastroenterol Hepatol 2017;32:82-91.
70. Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, et al. EBV microRNA-BHRF1-2-5p targets the 3’UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood 2019;134:2261-70.
71. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog 2012;8:e1002484.
72. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015;43:D153-9.
73. Yoon CJ, Chang MS, Kim DH, Kim W, Koo BK, et al. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas. Gastric Cancer 2020. epub ahead of print [PMID: 32206940 doi: 10.1007/s10120-020-01059-3]
74. Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med 2018;24:1877-86.
75. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
76. Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 2017;47:1083-99.e6.
77. Seo AN, Kang BW, Bae HI, Kwon OK, Park KB, et al. Exon 9 mutation of PIK3CA associated with poor survival in patients with Epstein-Barr virus-associated gastric cancer. Anticancer Res 2019;39:2145-54.
78. Song M, Chen D, Lu B, Wang C, Zhang J, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013;8:e65821.
79. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
80. Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer 2019;145:916-26.
81. Menyhárt O, Pongor LS, Győrffy B. Mutations defining patient cohorts with elevated PD-L1 expression in gastric cancer. Front Pharmacol 2018;9:1522.
82. Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 2018;109:43-53.
83. Zhang Y, Liu W, Zhang W, Wang W, Song Y, et al. Constitutive activation of the canonical NF-κB signaling pathway in EBV-associated gastric carcinoma. Virology 2019;532:1-10.
84. Shi Q, Zhang Y, Liu W, Xiao H, Qi Y, et al. Latent membrane protein 2A inhibits expression level of Smad2 through regulating miR-155-5p in EBV-associated gastric cancer cell lines. J Med Virol 2020;92:96-106.
85. Iwakiri D, Minamitani T, Samanta M. Epstein-Barr virus latent membrane protein 2A contributes to anoikis resistance through ERK activation. J Virol 2013;87:8227-34.
86. Qi YF, Liu M, Zhang Y, Liu W, Xiao H, et al. EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer. Virus Res 2019;272:197735.
87. Li H, Xia JQ, Zhu FS, Xi ZH, Pan CY, et al. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation. J Cell Biochem 2018;119:9997-10004.
88. Wang X, Wu WKK, Gao J, Li Z, Dong B, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res 2019;38:140.
89. Xu D, Li J, Li RY, Lan T, Xiao C, et al. PD-L1 Expression is regulated by NF-κB during EMT signaling in gastric carcinoma. Onco Targets Ther 2019;12:10099-105.
90. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009;69:2766-74.
91. Cai L, Ye Y, Jiang Q, Chen Y, Lyu X, et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat Commun 2015;6:7353.
92. Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 2015;34:2156-66.
93. Moon JW, Kong SK, Kim BS, Kim HJ, Lim H, et al. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep 2017;7:17810.
94. Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer 2017;20:407-15.
95. Li Z, Lai Y, Sun L, Zhang X, Liu R, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol 2016;55:182-9.
96. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2017;66:794-801.
97. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-67.
98. Billiau A. Interferon-γ: biology and role in pathogenesis. Advances in Immunology Volume 62. Elsevier; 1996. pp. 61-130.
99. Jiang X, Wang J, Deng X, Xiong F, Ge J, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019;18:10.
100. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
101. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006;580:755-62.
102. Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015;4:e1008824.
103. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 2009;217:21-31.
104. Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Gastric Cancer 2019;22:486-96.
105. Fang W, Zhang J, Hong S, Zhan J, Chen N, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014;5:12189-202.
106. Su S, Zou Z, Chen F, Ding N, Du J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. OncoImmunology 2016;6:e1249558.
107. Nakayama A, Abe H, Kunita A, Saito R, Kanda T, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. PLoS One 2019;14:e0211358.
108. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009;206:2091-9.
